Loading...
Generating destination analysis
Compass Direction
Earnings IntelligenceAI-Powered
Loading earnings analysis...
Compass Score
Favorable
Unlock Full LLY Analysis
UpgradeKey Numbers
Market Cap
$750B
P/E
65
Revenue Growth
+32.0%
Gross Margin
N/A
ROE
N/A
About Eli Lilly and Company
Eli Lilly and Company (LLY) is a mega-cap NYSE-listed company in the pharma space, blending biotech and genomics initiatives alongside its core business operations. Pharma giant leading the GLP-1 revolution with Mounjaro and Zepbound weight-loss drugs. Valued at 65x trailing earnings with a $750B market capitalization, Eli Lilly and Company has delivered rapid top-line expansion with revenue moving +32% over the past year.
Expert Coverage
Loading coverage...
Price & Technical Analysis
Price50 DMA200 DMA
Price vs 200DMA
DMA Convergence
50 DMA
200 DMA
Rating last updated: 2026-03-28
More in Biotech & Genomics
ARKG
ARK Genomic Revolution ETF
89
True North
Mixed
ETF focused on companies advancing genomics, gene editing, and therapeutics.
CBOE
MCap $2BDXCM
DexCom Inc.
85
True North
Pure Play
Continuous glucose monitoring leader expanding beyond diabetes management.
NASDAQ
MCap $35BRev +20%P/E 55ALNY
Alnylam Pharmaceuticals
85
True North
Pure Play
RNA interference therapeutics leader with approved treatments for rare diseases.
NASDAQ
MCap $30BRev +40%BEAM
Beam Therapeutics
84
True North
Pure Play
Base editing platform with differentiated gene-editing pipeline.
NASDAQ
MCap $3B